277 related articles for article (PubMed ID: 30268412)
1. A new carbapenem drug dosage metric for carbapenem usage and correlation with carbapenem resistance of Pseudomonas aeruginosa.
Hirayama S; Yasui K; Murakami H; Kosugi T; Sakamoto M; Hanai Y; Matsuo K; Miyazaki T; Ishii Y; Nishizawa K; Tateda K
J Infect Chemother; 2018 Dec; 24(12):949-953. PubMed ID: 30268412
[TBL] [Abstract][Full Text] [Related]
2. Impact of carbapenem restriction on the antimicrobial susceptibility pattern of Pseudomonas aeruginosa isolates in the ICU.
Abdallah M; Badawi M; Amirah MF; Rasheed A; Mady AF; Alodat M; Alharthy A
J Antimicrob Chemother; 2017 Nov; 72(11):3187-3190. PubMed ID: 28961733
[TBL] [Abstract][Full Text] [Related]
3. Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study.
Mladenovic-Antic S; Kocic B; Velickovic-Radovanovic R; Dinic M; Petrovic J; Randjelovic G; Mitic R
J Clin Pharm Ther; 2016 Oct; 41(5):532-7. PubMed ID: 27511808
[TBL] [Abstract][Full Text] [Related]
4. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa.
Fujimura S; Nakano Y; Sato T; Shirahata K; Watanabe A
J Infect Chemother; 2007 Jun; 13(3):147-50. PubMed ID: 17593500
[TBL] [Abstract][Full Text] [Related]
5. Prospective monitoring of carbapenem use and pseudomonal resistance across pediatric institutions.
Miyairi I; Shoji K; Kinoshita N; Saitoh J; Sugahara Y; Watanabe Y; Komura M; Kasai M; Horikoshi Y; Shinjoh M; Igarashi T;
Infect Control Hosp Epidemiol; 2020 Sep; 41(9):1042-1047. PubMed ID: 32484118
[TBL] [Abstract][Full Text] [Related]
6. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
9. Relation between the antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from respiratory specimens and antimicrobial use density (AUD) from 2005 through 2008.
Fukushima Y; Fukushima F; Kamiya K; Hayashi Y; Tatewaki M; Yamada I; Hirata H; Sugiyama K; Ishii Y; Fukuda T
Intern Med; 2010; 49(14):1333-40. PubMed ID: 20647645
[TBL] [Abstract][Full Text] [Related]
10. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
Luyt CE; Aubry A; Lu Q; Micaelo M; Bréchot N; Brossier F; Brisson H; Rouby JJ; Trouillet JL; Combes A; Jarlier V; Chastre J
Antimicrob Agents Chemother; 2014; 58(3):1372-80. PubMed ID: 24342638
[TBL] [Abstract][Full Text] [Related]
11. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
[TBL] [Abstract][Full Text] [Related]
12. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
Cook PP; Gooch M; Rizzo S
Antimicrob Agents Chemother; 2011 Dec; 55(12):5597-601. PubMed ID: 21968357
[TBL] [Abstract][Full Text] [Related]
13. [Shall we report the carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii strains detected by BD Phoenix system?].
Oğünç D; Ongüt G; Ozen NS; Baysan BO; Günseren F; Dağlar D; Demirbakan H; Gültekin M
Mikrobiyol Bul; 2010 Apr; 44(2):197-202. PubMed ID: 20549953
[TBL] [Abstract][Full Text] [Related]
14. Correlation between the consumption of meropenem or doripenem and meropenem susceptibility of Pseudomonas aeruginosa in a university hospital in Japan.
Miyawaki K; Miwa Y; Seki M; Asari S; Tomono K; Kurokawa N
Biol Pharm Bull; 2012; 35(6):946-9. PubMed ID: 22687536
[TBL] [Abstract][Full Text] [Related]
15. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
Nicolau DP; Carmeli Y; Crank CW; Goff DA; Graber CJ; Lima AL; Goldstein EJ
Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702
[TBL] [Abstract][Full Text] [Related]
16. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
Carmeli Y; Lidji SK; Shabtai E; Navon-Venezia S; Schwaber MJ
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):367-72. PubMed ID: 21683268
[TBL] [Abstract][Full Text] [Related]
17. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of antimicrobial use density (AUD) of carbapenem antibacterial agents and investigation of the drug susceptibility of Pseudomonas aeruginosa in 3 hospitals in southern Ibaraki Prefecture, Japan].
Oishi T; Hitomi S; Kamoshita M; Fukue H; Kawahata D; Fukutake K
Rinsho Byori; 2008 Jul; 56(7):570-6. PubMed ID: 18709988
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
20. Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis.
Baditoiu L; Axente C; Lungeanu D; Muntean D; Horhat F; Moldovan R; Hogea E; Bedreag O; Sandesc D; Licker M
Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):71. PubMed ID: 29132352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
